Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

Background: ExteNET showed that 1 year of neratinib, an irreversible pan-HER tyrosine kinase inhibitor, significantly improves 2-year invasive disease-free survival after trastuzumab-based adjuvant therapy in women with HER2-positive breast cancer. We report updated efficacy outcomes from a protocol...

Full description

Bibliographic Details
Main Authors: Martin, M., Holmes, F., Ejlertsen, B., Delaloge, S., Moy, B., Iwata, H., von Minckwitz, G., Chia, S., Mansi, J., Barrios, C., Gnant, M., Tomaševic, Z., Denduluri, N., Šeparovic, R., Gokmen, E., Bashford, A., Ruiz Borrego, M., Kim, S., Jakobsen, E., Ciceniene, A., Inoue, K., Overkamp, F., Heijns, J., Armstrong, A., Link, J., Joy, A., Bryce, R., Wong, A., Moran, S., Yao, B., Xu, F., Auerbach, A., Buyse, M., Chan, Arlene, ExteNET Study Group
Format: Journal Article
Published: The Lancet Publishing Group 2017
Online Access:http://hdl.handle.net/20.500.11937/59410

Internet

http://hdl.handle.net/20.500.11937/59410

Similar Items